Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neurapas balance
- Development stage
- Phase 1
- Lead developer
- Pascoe Naturmedizin
- Administration
- Oral
01
Overview
Neurapas balance is a herbal medicinal product developed and manufactured by Pascoe Pharmazeutische Praeparate GmbH. It is a fixed-dose combination of three standardized plant extracts: *Hypericum perforatum* (St. John's Wort), *Passiflora incarnata* (Passionflower), and *Valeriana officinalis* (Valerian). The product is indicated for the treatment of mild to moderate depressive episodes accompanied by anxiety, nervous restlessness, and sleep disturbances. Its therapeutic effect is derived from the synergistic action of its components: St. John's Wort acts as a multi-reuptake inhibitor of serotonin, norepinephrine, and dopamine; Passionflower provides anxiolytic properties through GABAergic modulation; and Valerian serves as a mild sedative. Clinical trials have utilized quantitative EEG to demonstrate its pharmacological effects on brain activity, confirming its impact on central nervous system function.
- Brand names
- Neurapas balance
- Other names
- hypericum + passionflower + valerianSt. John’s Wort + passionflower + valerianHypericum perforatum + Passiflora incarnata + Valeriana officinalis
02
Targets
DAT (Dopamine plasma membrane transport protein)GABRR (GABA-A receptor subunit rho)MTNR1A (MT1)NET (Norepinephrine Transporter)HTR2C (5-hydroxytryptamine 2C receptor)SERT (Sodium-dependent serotonin transporter)GABA-B (Gamma-aminobutyric acid receptor type B)
Beyond the preview
Go deeper on Neurapas balance.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neurapas balance.